About: Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $7.14 (+4.69%)
OCUL NASDAQ Ocular Therapeutix Inc
Ocular Therapeutix Inc share price
OCUL price activity
Last Price
$7.140
Change (24hr)
0.32 USD (4.69%)
Volume
3.36M
Volume (4w avg)
-
Open
$7.09
Day Range
$6.83 - $7.17
Previous Close
$6.82
Last Trade
04 Nov, 9:00 pm GMT+0
Delayed
04 Nov, 9:00 pm GMT+0
OCUL price performance
Delayed
04 Nov, 9:00 pm GMT+0
OCUL details
OCUL Market Signals